Lisata Therapeutics
LSTA
22 hedge funds and large institutions have $1.84M invested in Lisata Therapeutics in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
5% more funds holding
Funds holding: 21 → 22 (+1)
0.27% less ownership
Funds ownership: 9.35% → 9.09% (-0.27%)
21% less capital invested
Capital invested by funds: $2.33M → $1.84M (-$493K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$184K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$27.8K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$15.9K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$12.5K |
| 5 |
Renaissance Technologies
New York
|
+$3.79K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$184K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$69.4K |
| 3 |
BlackRock
New York
|
-$3.13K |
| 4 |
SS
SBI Securities
Tokyo,
Japan
|
-$1.08K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$11 |
LSTA Hedge Fund Activity: Q1 2025 in Review
22 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q1 2025, worth a combined $1.84M — down 21% from $2.33M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new LSTA positions and 2 closed out — a net gain of 1 holder — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $184K. The largest seller was BML Capital Management, cutting an estimated $184K.
- 22 institutional investors held Lisata Therapeutics (LSTA) as of Q1 2025, up from 21 in Q4 2024.
- Funds reported $1.84M of Lisata Therapeutics stock for Q1 2025, down 21% quarter-over-quarter.
- 3 funds opened new Lisata Therapeutics positions in Q1 2025 and 2 closed out, a net change of +1 holder.
- The largest Lisata Therapeutics buyer in Q1 2025 was Vanguard Group, an estimated $184K added.
- The largest Lisata Therapeutics seller in Q1 2025 was BML Capital Management, an estimated $184K sold.
Based on aggregated 13F filings for Q1 2025.